|
|
|
| Research progress of Curcumin and Resveratrol in the treatment of non-alcoholic fatty liver disease |
| HE Yuhui1 ZHU Mingxing2 LIU Yueyang3 ZHAO Ruowei1 HUANG Mingqing1 SHI Hong4 ZHENG Yanfang1 LIN Yanxiang1 |
1.College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian Province, Fuzhou 350100, China;
2.College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Fujian Province, Fuzhou 350122, China;
3.College of Acupuncture and Moxibustion, Fujian University of Traditional Chinese Medicine, Fujian Province, Fuzhou 350122, China;
4.College of Integrated Traditional Chinese and Western Medicine, Fujian University of Traditional Chinese Medicine, Fujian Province, Fuzhou 350122, China |
|
|
|
Abstract Non-alcoholic fatty liver disease (NAFLD) is defined as liver disease characterized by fat accumulation caused by factors other than alcohol consumption. The pathogenesis of NAFLD is complex, including insulin resistance, mitochondrial dysfunction, intestinal flora disorder and other factors affecting the occurrence and development of NAFLD, and the activation of nuclear factor-κB signaling pathway and lipid overaccumulation may also be involved. Clinically, there is a lack of ideal drugs for NAFLD treatment, and the current treatment methods are mainly to reduce weight by regulating lifestyle and improve the components of metabolic syndrome to alleviate the disease. Curcumin and resveratrol, both polyphenols, have been found to be potential drugs for the treatment of NAFLD, and extensive experimental studies have been carried out. This paper systematically summarizes the research progress on the mechanism of curcumin and resveratrol in the treatment of NAFLD, providing theoretical basis for the subsequent treatment of NAFLD and the clinical application of curcumin and resveratrol.
|
|
|
|
|
|
[1] Sanyal AJ. Past，present and future perspectives in nonalcoholic fattyliver disease [J]. Nat Rev Gastroenterol Hepatol，2019，16（6）：377-386.
[2] 张欣欣.降脂保肝汤对非酒精性脂肪性肝病的作用观察[J].中国中医药科技，2022，29（4）：671-673.
[3] 赵瀚东，杨帆，詹丽.非酒精性脂肪性肝病发病机制研究进展[J].解放军医学院学报，2022，43（3）：366-371.
[4] 李玉倩，李学军.姜黄素抗肿瘤作用基础与临床研究进展[J].中国药理学与毒理学杂志，2020，34（5）：321-335.
[5] 任珊，丁琳，李清禹，等.白藜芦醇对高脂饮食诱导小鼠高脂血症的作用机制研究[J].中国临床药理学杂志，2022， 38（2）：137-141.
[6] 岳映东，杨维杰，康学东，等.运用网络药理学及分子对接方法探讨化浊胶囊治疗非酒精性脂肪肝及改善胰岛素抵抗的机制[J].实用中医内科杂志，2022，36（2）：1- 5，143-145.
[7] 晓艳，张英，郭晶.西格列汀对2型糖尿病患者体质量与胰岛素抵抗的影响[J].贵州医药，2021，45（10）：1549- 1550.
[8] 吴蓝蓝，戈宏焱，梁东亮，等.非酒精性脂肪性肝病发病机制的研究进展[J].中外医学研究，2021，19（13）：193- 196.
[9] Zou T，Li S，Wang B，et al. Curcumin improves insulin sensitivity and increases energy expenditure in high-fat-diet-induced obese mice associated with activation of FNDC5/ irisin [J]. Nutrition，2021，90111263.
[10] Du F，Huang R，Lin D，et al. Resveratrol Improves Liver Steatosis and Insulin Resistance in Non-alcoholic Fatty Liver Disease in Association With the Gut Microbiota [J]. Front Microbiol，2021，12611323.
[11] 谢鹏超，邱利焱.纳米载体在非酒精性脂肪肝药物治疗中的研究进展[J].中国现代应用药学，2021，38（13）：1610- 1617．
[12] Lee ES，Kwon MH，Kim HM，et al. Curcumin analog CUR5- 8 ameliorates nonalcoholic fatty liver disease in mice with high-fat diet-induced obesity [J]. Metabolism，2020，10315 4015.
[13] 廖梦君.姜黄素对非酒精性脂肪肝细胞自噬的影响[D].衡阳：南华大学，2019.
[14] Ding S，Jiang J，Zhang G，et al. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats [J]. PLoS One，2017，12（8）：e183541.
[15] Fang C，Cai X，Hayashi S，et al. Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease [J]. Biochim Biophys Acta Mol Cell Biol Lipids，2019， 1864（3）：271-280.
[16] 王亚涛，程妍，徐静远，等.非酒精性脂肪肝病大鼠肠道菌群对肠促胰素效应的影响[J].复旦学报（医学版），2022，49（3）：332-338.
[17] Li S，You J，Wang Z，et al. Curcumin alleviates high-fat diet-induced hepatic steatosis and obesity in association with modulation of gut microbiota in mice [J]. Food Res Int，2021，143110270.
[18] Chen M，Hou P，Zhou M，et al. Resveratrol attenuates high- fat diet-induced non-alcoholic steatohepatitis by maintaining gut barrier integrity and inhibiting gut inflammation through regulation of the endocannabinoid system [J]. Clin Nutr，2020，39（4）：1264-1275.
[19] 董文娟，杨立宏，张文佳.降脂瘦身汤对非酒精性脂肪肝大鼠脂代谢及核转录因子-κB蛋白表达影响的实验研究[J].陕西中医，2021，42（8）：1016-1019.
[20] Li CX，Gao JG，Wan XY，et al. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-kappaB signaling pathways [J]. World J Gastroenterol，2019，25（34）：5120-5133.
[21] Weisberg SP，Leibel R，Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity [J]. Endocrinology，2008，149（7）：3549-3558．
[22] Y Tian，Ma J，Wang W，et al. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKalpha-SIRT1 pathway in mice with fatty liver [J]. Mol Cell Biochem，2016，422（1/2）：75-84.
[23] 于温温，张金华，刘云娜，等.贻贝多糖对高脂饮食诱导的载脂蛋白E基因敲除小鼠非酒精性脂肪肝的改善作用[J].食品工业科技：1-9[2022-07-14].
[24] Zhang N，Wang Y，Zhang J，et al. N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPARalpha and SCD-1 [J]. FASEB J，2020，34（11）：15338-15363.
[25] 李辉，刘志虎，李华，等.姜黄素脂质体对高脂诱导的非酒精性脂肪性肝病小鼠的降脂保肝作用[J].中国医药，2020，15（7）：1053-1057.
[26] 陈仲生.姜黄素对高脂饮食诱导的NAFLD大鼠肝脏保护作用的研究[D].锦州：锦州医科大学，2020.
[27] 苗向霞，郭蕊，张璎，等.白藜芦醇对肝癌HepG_2细胞中脂肪合成的抑制作用及其机制[J].吉林大学学报（医学版），2019，45（1）：69-72.
[28] AlBasher G，Abdel-Daim MM，Almeer R，et al. Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats [J]. Environ Sci Pollut Res Int，2020，27（6）：6505-6514.
[29] Zhou X，Afzal S，Zheng YF，et al. Synergistic Protective Effect of Curcumin and Resveratrol against Oxidative Stress in Endothelial EAhy926 Cells [J]. Evid Based Complement Alternat Med，2021，20212661025.
[30] Yan T，Yan N，Wang P，et al. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease [J]. Acta Pharm Sin B，2020，10（1）：3-18. |
|
|
|
